First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, March 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 8 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 21 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 10 X posts from 8 X users, with an upper bound of 74,473 followers.

RT @JournalofExper1: 📢New issue now online! First-in-human phase 1 #clinicaltrial of anti-core 1 O-glycans targeting #monoclonalantibody N…

06 Apr 2023

Reply Repost Favourite

RT @exosome: First in human proof of concept study exploring an antibody that binds only to #cancer based on expression of (CEACAM)-5 and…

03 Apr 2023

Reply Repost Favourite

First in human proof of concept study exploring an antibody that binds only to #cancer based on expression of (CEACAM)-5 and CEACAM-6 variants https://t.co/blfsFturaV

02 Apr 2023

Reply Repost Favourite

RT @JournalofExper1: 📢New issue now online! First-in-human phase 1 #clinicaltrial of anti-core 1 O-glycans targeting #monoclonalantibody N…

31 Mar 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.